Good afternoon, and welcome to the Sera Prognostics Conference Call to review Third Quarter Fiscal Year 2024 Results. [Operator Instructions] As a reminder, the call is being recorded for replay purposes. I would now like to turn the call over to Peter DeNardo of Capcomm Partners for a few introductory comments.

Thank you, operator. Good afternoon, everyone. Welcome to Sera Prognostics Third Quarter Fiscal Year 2024 Earnings Conference Call. At the close of the market today, Sera Prognostics released its financial results for the quarter ended September 30, 2024. Presenting for the company today will be Evguenia Lindgardt, President and CEO; and Austin Aerts, our CFO. During the call, we will review the financial results we released today, after which we will host a question-and-answer session. If you've not had a chance to review our quarterly earnings release, it can be found on our website at seraprognostics.com. This call can be heard live via webcast at seraprognostics.com, and a recording will be archived in the Investors section of our website. Please note that, some of the information presented today may contain projections, or other forward-looking statements about events and circumstances that have not yet occurred, including plans and projections for our business, future financial results and market trends and opportunities. These statements are based on management's current expectations, and the actual events or results may differ materially and adversely from these expectations for a variety of reasons. We refer you to the documents the company files from time to time with the Securities and Exchange Commission, specifically the company's annual report on Form 10-K, its quarterly reports on Form 10-Q and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in our projections and other forward-looking statements. As a reminder, a webcast replay of this call will be available on the Investors section of our website. I will now turn the call over to Evguenia, Sera Prognostics President and CEO. Evguenia?

Thank you so much, Peter, and good afternoon, everyone. We're solidly executing our plan for the year to support increases in test adoption and revenue. This plan, which we've communicated previously, focuses on publication of our clinical trial results, building awareness of PRETERM birth screening risks and Sera solutions, increasing payer coverage, making it easier to access our test, putting scalability in place to harness that growth. Once established, these prerequisites are expected to be the engine of our growth, fueled by the critical need we can and will fulfill in improving maternal health care outcomes for mothers and babies. Following the publication of our positive AVERT PRETERM TRIAL results on the front cover of the July issue of the International peer-reviewed journal diagnostics, we are eagerly pursuing publication of PRIME results. As we discussed last quarter, we're now seeking publication of these results in the key pregnancy and maternal health conferences in the spring and a manuscript submission to a high-quality peer-reviewed journal. The AVERT publication solidly demonstrated that the health risks of babies can be improved in asymptomatic pregnant mothers without typical risk factors. We believe publication of the final PRIME clinical study results could prove even more compelling in supporting the benefits of our PreTRM Test, coupled with a test and treat program. We locked our database a few weeks ago and are actively working towards publication and abstract submissions. We will update you as more news becomes available on our progress. While we await this further evidence to become available, we've made progress towards other prerequisites that are required to grow our business commercially. Before I lay out updates to our commercialization progress, I'd like to take a moment to detail how significant the health care problem is that we are addressing, and how it represents…

Thanks, Evguenia, and good afternoon, everyone. Let me review our financial results for the quarter. Afterward, I'll briefly touch on our view of managing operating expenses while investing where we need to such that once our prerequisites have been achieved, we can begin accelerating towards revenue growth. Net revenue for the third quarter of 2024 was $29,000 compared to $42,000 for the same period a year ago. Our plan for the year has called for making very careful, cost-effective and select investments that we believe will drive commercial sales to a higher magnitude in future quarters, and this quarterly revenue level reflects that plan accordingly. With that in mind, total operating expenses for the third quarter of $8.9 million were up 8% from $8.2 million for the same period a year ago. Net loss for the quarter was up 10% to $7.9 million compared to $7.2 million for the third quarter of 2023. About 2/3s of the increased operating costs and net loss year-over-year was due to an increase in noncash stock compensation expense, due to our higher stock price. Adjusting for this, our costs and net loss were relatively flat year-over-year, with only a modest 3% increase. Research and development expenses were $3.5 million, and approximately flat with the third quarter of 2023. Selling, general and administrative expenses for the third quarter were $5.4 million, and up from $4.6 million for the same period a year ago, due primarily to our selected investment in anticipated growth drivers, costs associated with filing our shelf registration and increased stock compensation expense. As of September 30, 2024, the company had cash, cash equivalents and available-for-sale securities of approximately $74.3 million. In 2024, our gross cash expense is expected to be less than $30 million, with many of our expenses focused on evidence generation, building foundations for scalability and awareness, making select investments in market broadening opportunities, enhancing some of our commercial capabilities, and product development. As we begin planning for the year ahead, we are targeting gross cash expenses to remain under that threshold, while we begin allocating more towards commercial activity than in 2024. Therefore, with a projected year-end cash balance of approximately $68 million, we believe we have cash into 2027 before assuming any future revenues. Operator, we can now open the call for questions.

[Operator Instructions] Andrew Brackmann from William Blair.

Maybe on your comments related to sort of the timing precedent here for guidelines. First, could you maybe just clarify your time line expectations here for PreTRM? And I guess, secondly, I know a lot is not in your control with respect to these guideline bodies actually moving it through their own processes. But can you maybe sort of talk about the levers that are in your control and how you're ensuring to make that process go smoothly and hopefully quickly?

Definitely. Thank you so much for your question, Andrew. Good to hear you. ACOG frequently looks at other guideline bodies, for example, in this case, a Society for Maternal and Fetal Medicine, SMFM to inform their physician. And there is an existing ACOG bulletin with guidelines. So they will not be developing it from white space, de novo. It would be a consideration for an update, which frequently starts with a commentary letter on a publication. That would be the first meaningful milestone to look out for. Society for Maternal and Fetal Medicine typically comments on 20, 30 publications a year. We are excited about PRIME results, and we, of course, will be eagerly waiting to see the reaction of the society to our results as the first green shoot. The common next milestones would include practice advisory or a practice bulletin. Those usually come later as the questions from the community to the society come up on what is the position of the society on care guidelines of this innovation. We think -- again, we don't have a crystal ball, unfortunately, but we think that, that will come in time. But of course, it will start with a key milestone, PRIME peer-reviewed publication. Until that event, we don't expect any significant signals from the societies, SMFM or ACOG. We should also consider and are developing strategies for other USPS task force, for example, and we'll keep the community updated on our progress towards these. Overall, the #1 lever is the quality of our data, Andrew, to your question, what can we control. And that's why we invested so much in our pivotal PRIME study to make sure that the quality of that evidence, the quality of the analytical methods, the input we got and the work of the PIs in that study will speak for itself to the guideline setting body influencers.

Terrific. And then I just want to go back to your comments sort of around your discussion or ongoing discussions with payers. Can you maybe just sort of talk to us about this at a high level? I guess, from your perspective, what gets them across the finish line here? Will it be PRIME results? Will it be something else? It seems to me that, this is a test that sort of makes common sense for them to bring under coverage. So in your view, what sort of gets them to move there?

Absolutely. Program minimum is a quality peer-reviewed publication, which PRIME will be. And of course, coupled with AVERT, it will be really strong evidence base for the potential of PreTRM Test and treat program. Second, of course, is the economic modeling. Here, we're very fortunate to have a few tools to make available for payers. Number one, of course, is Elevance modeling of their own population that delivered results, published results of $1,600 of savings per member tested on about 40,000 members they've modeled. Our partners, Elevance, will also be modeling economic impact on the PRIME study subjects that were Elevance members, and that will be additional evidence that will absolutely be considered by all the other payers reviewing the PreTRM Test for coverage. We also put together a model we'll make available as we begin discussions with all of the payers, where they can put in their own cost of care and members' characteristics so that they can see what covering PreTRM Test can do for their cost of care reductions and cost savings as well as the potential to improve care in some of their Medicaid plans. So those 2 key levers will be absolutely essential. And as you can imagine, we're working very hard on a great peer-reviewed publication of PRIME. And as I described, we have a really strong economic evidence to put in front of payers. With that, I think there will be particular payers, and we are happy to talk more about that next quarter that will jump on the opportunity for cost of care savings early. Others will follow. It will be a process over many years, but we hope that, that process will start robustly post PRIME publication.

[Operator Instructions] There are no further questions at this time. I'd now like to turn the call over to Evguenia Lindgardt for final closing comments.

Thank you, operator. Thank you so much, everyone, for attending our call today. We look forward to the expected publication of our pivotal PRIME clinical study results and continuing to propel our company towards commercial success. Although, we have plenty of work to do in the final weeks of 2024, this has been a great year for Sera Prognostics and we thank our shareholders for their support. I'll now turn it back over to the operator to conclude the call. Operator?

Ladies and gentlemen, this concludes your conference call for today. We thank you for participating and ask that you please disconnect your lines.